Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship

After updating our health system’s Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadhe...

Full description

Saved in:
Bibliographic Details
Published inInfection control and hospital epidemiology Vol. 44; no. 2; pp. 312 - 314
Main Authors Khadem, Tina M., Nguyen, M. Hong, Bariola, J. Ryan
Format Journal Article
LanguageEnglish
Published New York, USA Cambridge University Press 01.02.2023
Subjects
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Antimicrobial Stewardship
Clinical practice guidelines
Clostridioides
Clostridioides difficile
Clostridium Infections - drug therapy
Concise Communication
Diarrhea
Disease control
Drug therapy
Fidaxomicin - therapeutic use
Hospitals
Hospitals, Community
Humans
Infectious diseases
Patients
Pharmacy
antimicrobial stewardship
fidaxomicin
Online AccessGet full text

Cover

More Information
Summary:After updating our health system’s Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadherent. Antimicrobial stewardship programs are important for facilitating best practices, even among ID specialists.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PREVIOUS PRESENTATION. Part of this information was presented as an abstract at IDWeek 2019, on October 2–6, 2019, in Washington, DC.
ISSN:0899-823X
1559-6834
DOI:10.1017/ice.2021.456